News

Genzyme has reported that a four-year follow-up data from its completed phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation

Takeda and its wholly-owned subsidiary, Millennium Pharmaceuticals have initiated stage II of a phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer. TAK-700 is a

Access Pharmaceuticals (Access) has entered into an agreement with a commercial manufacturer, Accupac, to produce its FDA-approved MuGard for North American distribution. MuGard is a novel, ready-to-use mucoadhesive

The FDA has accepted for review Merz Pharmaceuticals’ (Merz) premarket approval (PMA) application for Belotero Balance. Belotero Balance is a hyaluronic acid-based monophasic gel dermal filler that utilizes

American Oriental Bioengineering (AOBO) has launched a new over-the-counter (OTC) product – YuYeQingHuo Capsules (YYQH). YYQH will be manufactured by the company’s Boke subsidiary. It will be marketed

Sanofi-aventis has reported the results of a phase II study with teriflunomide, a novel orally available immunomodulatory therapy for multiple sclerosis (MS). Teriflunomide is currently being explored in

AkzoNobel is planing to balance its Performance Coatings and Specialty Chemicals portfolios as part of a realignment which will see the launch of two new business units and

Arpida and Evolva, two Swiss biotech companies, have announced that they intend to merge the two companies subject to definitive agreement and shareholder approval. The company said that

Galapagos has initiated a second phase I clinical trial for GLPG0259, a novel candidate drug being developed for rheumatoid arthritis (RA). The new trial is based on the